Buffett Dumps $800M Of Apple, Buys This Instead!
Warren Buffett recently dumped $800 million of Apple stock…

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…
What does Buffett know?

ONCS Insider Trading (OncoSec Medical)

Insider Ownership Percentage: 0.71%
Insider Buying (Last 12 Months): $29,961,451.65
Insider Selling (Last 12 Months): $725,043.04

OncoSec Medical Insider Trading History Chart

OncoSec Medical Share Price & Price History

$5.71
▲ +0.21 (3.82%)
As of 03/1/2021 01:00 AM ET
Days: 30 | 90 | 365
Biden Era Puts Spotlight on Green-Energy Profit-Stocks
With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $0.25 per share, that’s advancing the largest green-energy asset in an entire country.
More Here...
pixel

OncoSec Medical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2021Daniel J O'connorCEOSell3,413$7.71$26,314.2399,269  
1/25/2021Grand Pharmaceutical & H ChinaMajor ShareholderBuy4,067,037$5.45$22,165,351.65  
11/20/2020Alpha Holdings, Inc.DirectorSell80,000$4.92$393,600.001,350,001  
11/18/2020Alpha Holdings, Inc.DirectorSell10,999$5.24$57,634.761,480,001  
11/16/2020Alpha Holdings, Inc.DirectorSell40,000$5.41$216,400.00  
11/2/2020Daniel J O'connorCEOSell3,280$3.79$12,431.20102,682  
8/19/2020Grand Pharmaceutical & H ChinaMajor ShareholderBuy2,398,800$3.25$7,796,100.00  
7/31/2020Daniel J O'connorCEOSell3,133$4.20$13,158.60105,962  
4/30/2020Daniel J O'connorCEOSell3,075$1.79$5,504.2562,986  
1/31/2020Daniel J O'connorCEOSell2,654$1.96$5,201.8466,061  
1/16/2020Sara BonsteinCFOSell1,351$2.08$2,810.0841,389  
10/31/2019Daniel J O'connorCEOSell2,128$2.16$4,596.4868,715  
10/16/2019Sara BonsteinCFOSell1,111$2.01$2,233.1142,740  
7/16/2019Alpha Holdings, Inc.DirectorBuy90,000$2.30$207,000.00  
5/22/2019Alpha Holdings, Inc.DirectorBuy491,000$3.14$1,541,740.0010,491,000  
11/20/2018James M DemesaDirectorBuy8,500$0.82$6,970.0014,001  
11/7/2018Daniel J O'connorCEOBuy10,000$0.91$9,100.0026,667  
11/7/2018James M DemesaDirectorBuy1,500$0.91$1,365.0014,001  
7/5/2018Avtar S DhillonDirectorSell37,575$1.39$52,229.25181,002  
7/5/2018Richard B SlanskyCFOSell84,984$1.39$118,127.76255,000  
6/29/2018Punit DhillonDirectorSell5,401$1.38$7,453.38355,702  
6/29/2018Richard B SlanskyCFOSell2,420$1.38$3,339.60255,000  
6/27/2018Punit DhillonDirectorSell17,480$1.37$23,947.60355,702  
6/27/2018Richard B SlanskyCFOSell7,832$1.37$10,729.84255,000  
6/25/2018Punit DhillonDirectorSell1,021$1.41$1,439.61355,702  
6/25/2018Richard B SlanskyCFOSell458$1.41$645.78255,000  
6/22/2018Punit DhillonDirectorSell14,976$1.42$21,265.92355,702  
6/22/2018Richard B SlanskyCFOSell6,710$1.42$9,528.20255,000  
6/20/2018Punit DhillonDirectorSell55,585$1.42$78,930.70355,702  
6/20/2018Richard B SlanskyCFOSell24,906$1.42$35,366.52255,000  
6/18/2018Punit DhillonDirectorSell28,145$1.39$39,121.55355,702  
6/18/2018Richard B SlanskyCFOSell12,613$1.39$17,532.07255,000  
See Full Table

SEC Filings (Institutional Ownership Changes) for OncoSec Medical (NASDAQ:ONCS)

4.15% of OncoSec Medical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

OncoSec Medical Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/16/2021One68 Global Capital LLC22,261$0.14M0.3%N/A0.080%
2/16/2021Price T Rowe Associates Inc. MD11,400$74K0.0%-33.2%0.041%
2/16/2021Avidity Partners Management LP1,952,000$12.59M0.4%N/A6.974%
2/16/2021ExodusPoint Capital Management LP18,854$0.12M0.0%N/A0.067%
2/12/2021Sandbox Financial Partners LLC75,000$0.48M0.4%N/A0.268%
2/11/2021Northern Trust Corp27,310$0.18M0.0%+94.9%0.098%
2/10/2021Renaissance Technologies LLC318,906$2.06M0.0%-20.8%1.139%
2/9/2021Sigma Planning Corp32,802$0.21M0.0%-26.0%0.117%
2/5/2021BlackRock Inc.60,526$0.39M0.0%+109.1%0.216%
1/30/2021Salzhauer Michael27,303$0.18M0.1%-15.5%0.098%
12/11/2020Virtu Financial LLC10,167$34K0.0%N/A0.036%
11/19/2020Schonfeld Strategic Advisors LLC27,900$95K0.0%N/A0.100%
11/17/2020Schonfeld Strategic Advisors LLC27,900$94K0.0%N/A0.101%
11/6/2020BlackRock Inc.28,941$98K0.0%-45.7%0.105%
11/3/2020Sigma Planning Corp44,302$0.15M0.0%-8.3%0.160%
8/10/2020D.A. Davidson & CO.118,500$0.24M0.0%+74.9%0.515%
7/31/2020Sigma Planning Corp48,302$99K0.0%+75.6%0.210%
5/1/2020Sigma Planning Corp27,502$35K0.0%N/A0.121%
2/13/2020Renaissance Technologies LLC198,519$0.36M0.0%+116.5%1.853%
2/10/2020Salzhauer Michael32,303$58K0.0%+127.5%0.302%
11/6/2019Salzhauer Michael14,200$28K0.0%N/A0.133%
11/5/2019D.A. Davidson & CO.24,000$47K0.0%N/A0.225%
8/14/2019Citadel Advisors LLC13,073$33K0.0%N/A0.123%
8/14/2019Worth Venture Partners LLC39,241$99K0.1%N/A0.370%
8/14/2019Vanguard Group Inc.174,640$0.44M0.0%-81.3%1.645%
8/14/2019Private Advisor Group LLC10,500$27K0.0%N/A0.099%
8/13/2019BlackRock Inc.32,568$82K0.0%-93.2%0.307%
8/13/2019Northern Trust Corp11,441$29K0.0%-90.0%0.108%
8/7/2019JPMorgan Chase & Co.18,085$46K0.0%N/A0.170%
2/15/2019Millennium Management LLC40,051$26K0.0%-43.0%0.062%
2/13/2019Geode Capital Management LLC388,688$0.25M0.0%+72.5%0.603%
2/12/2019Northern Trust Corp114,921$73K0.0%+33.6%0.178%
2/11/2019Moloney Securities Asset Management LLC50,000$32K0.0%+117.4%0.078%
2/11/2019Bank of New York Mellon Corp100,325$64K0.0%+484.1%0.156%
2/8/2019BlackRock Inc.485,983$0.31M0.0%+98.2%0.753%
11/15/2018Nexthera Capital LP1,388,824$1.94M0.4%-46.9%2.345%
11/15/2018Point72 Asset Management L.P.1,825,985$2.56M0.0%-17.6%3.083%
9/17/2018683 Capital Management LLC300,000$0.41M0.0%N/A0.573%
8/15/2018Millennium Management LLC1,195,315$1.65M0.0%+19.5%2.283%
8/15/2018Nexthera Capital LP2,614,297$3.61M0.6%+26.6%4.994%
8/14/2018Point72 Asset Management L.P.2,215,000$3.06M0.0%-31.1%4.231%
8/14/2018DRW Securities LLC180,000$0.25M0.0%+157.1%0.344%
8/9/2018BlackRock Inc.238,940$0.33M0.0%+1,303.5%0.456%
5/16/2018Millennium Management LLC1,000,576$1.88M0.0%+2,073.8%1.944%
5/16/2018Nexthera Capital LP2,064,297$3.88M0.6%N/A4.010%
5/15/2018Point72 Asset Management L.P.3,215,000$6.04M0.0%+47.5%6.245%
5/15/2018venBio Select Advisor LLC4,007,696$7.53M0.4%N/A7.785%
5/15/2018Sofinnova Ventures Inc66,965$0.13M0.0%N/A0.130%
5/14/2018DRW Securities LLC70,000$0.13M0.0%N/A0.136%
5/14/2018Commonwealth Equity Services LLC76,510$0.14M0.0%+97.6%0.149%
2/16/2018J. Goldman & Co LP100,000$0.16M0.0%N/A0.233%
2/15/2018Sabby Management LLC153,137$0.25M0.0%-84.8%0.357%
2/14/2018Deutsche Bank AG160,759$0.26M0.0%N/A0.374%
2/13/2018Renaissance Technologies LLC167,093$0.27M0.0%N/A0.389%
2/13/2018MYDA Advisors LLC89,000$0.15M0.1%N/A0.207%
5/15/2017Sabby Management LLC975,839$1.26M0.1%-16.9%4.676%
2/13/2017Renaissance Technologies LLC95,000$0.12M0.0%-39.6%0.481%
8/15/2016Sabby Management LLC608,052$1M0.1%-45.3%3.448%
5/13/2016Sabby Management LLC1,111,348$2.83M0.1%-9.2%6.549%
5/13/2016Renaissance Technologies LLC43,400$0.11M0.0%N/A0.256%
5/13/2016Geode Capital Management LLC57,031$0.15M0.0%No Change0.336%
2/16/2016Ridgeback Capital Investments L.P.1,292,614$3.06M13.2%N/A7.617%
1/13/2016Gierl Augustine Investment Management200$00.0%N/A0.001%
Data available starting January 2016

See Full Table
OncoSec Medical logo
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.
Read More

Today's Range

Now: $5.71
$5.51
$5.78

50 Day Range

MA: $6.77
$5.50
$7.71

52 Week Range

Now: $5.71
$1.04
$8.16

Volume

322,013 shs

Average Volume

354,546 shs

Market Capitalization

$159.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.64

Who are the company insiders with the largest holdings of OncoSec Medical?

OncoSec Medical's top insider shareholders include:
  1. Alpha Holdings, Inc (Director)
  2. Daniel J O'connor (CEO)
  3. Sara Bonstein (CFO)
  4. Grand Pharmaceutical & H China (Major Shareholder)

Who are the major institutional investors of OncoSec Medical?

OncoSec Medical's top institutional shareholders include:
  1. Avidity Partners Management LP — 6.97%
  2. Renaissance Technologies LLC — 1.14%
  3. Sandbox Financial Partners LLC — 0.27%
  4. BlackRock Inc. — 0.22%
  5. Sigma Planning Corp — 0.12%
  6. Northern Trust Corp — 0.10%

Which major investors are selling OncoSec Medical stock?

Within the last quarter, ONCS stock was sold by these institutional investors:
  1. Renaissance Technologies LLC
  2. Sigma Planning Corp
  3. Price T Rowe Associates Inc. MD
  4. Salzhauer Michael
During the previous year, company insiders that have sold OncoSec Medical company stock include:
  1. Alpha Holdings, Inc (Director)
  2. Daniel J O'connor (CEO)

Which major investors are buying OncoSec Medical stock?

In the last quarter, ONCS stock was purchased by institutional investors including:
  1. Avidity Partners Management LP
  2. Sandbox Financial Partners LLC
  3. BlackRock Inc.
  4. One68 Global Capital LLC
  5. ExodusPoint Capital Management LP
  6. Northern Trust Corp
In the previous year, these company insiders have bought OncoSec Medical stock:
  1. Alpha Holdings, Inc (Director)
  2. Daniel J O'connor (CEO)
The Best High Growth Cannabis Stock for 2021
An undiscovered Canadian company could be the next cannabis industry player to explode in Canada. With a unique strategy this company could be about to dominate the space and is trading under $1!
Continue Reading
pixel